CLINAM 9 / 2016 Conference and Exhibition
European & Global Summit for Cutting-Edge Medicine
June 26 – 29, 2016
Clinical Nanomedicine and Targeted Medicine -
Enabling Technologies for Personalized Medicine
Scientific Committee: Chairman • Prof. Dr. med. Patrick Hunziker, University Hospital Basel (CH). MEMBERS • Prof. Dr. Yechezkel Barenholz, Hebrew University, Hadassah Medical School, Jerusalem (IL). • Dr. med. h.c. Beat Löﬄer, MA, European Foundation for Clinical Nanomedicine, Basel (CH) • Prof. Dr. Gert Storm, Institute for Pharmaceutical Sciences, Utrecht University, (NL) • Prof. Dr. Marisa Papaluca Amati, European Medicines Agency, London (UK). • Prof. Dr. med. Christoph Alexiou, University Hospital Erlangen (D) • Prof. Dr. Gerd Binnig, Nobel Laureate, Munich (DE) • Prof. Dr. Viola Vogel, Laboratory for Biologically Oriented Materials, ETH, Zürich (CH).• Prof. Dr. Jan Mollenhauer, Lundbeckfonden Center of Excellence NanoCAN, University of Southern Denmark, Odense (DK).• Prof. Dr. med. Omid Farokhzad, Associate Professor and Director of Laboratory of Nanomedicine and Biomaterials, Harvard Medical School and Brigham and Women's Hospital; Founder of BIND Therapeutics, Biosciences and Blend Therapeutics, Cambridge, Boston (USA) Prof. Dr. Dong Soo Lee, M.D. Ph. Chairman Department of Nuclear Medicine Seoul National University Seoul, Korea (invited) Prof. Dr. Lajos Balogh, Editorin in Chief, Nanomedicine, Nanotechnologyin, Biology and Medicine, Elsevier  and Member  of the Executive Board, American Society for Nanomedicine in, Boston (USA) and other members.
The Conference at a Glance
In the previous eight years, the CLINAM Summit grew to the largest in its field with 12 presenting Noble Laureates and more than 500 participants from academia, industry, regulatory authorities and policy from over 40 different countries in Europe and worldwide. With this success and broad support by well beyond 20 renowned collaborating initiatives, the CLINAM-Summit is today one of the most important marketplaces for scientific exchange and discussions of regulatory, political and ethical aspects in this field of cutting edge medicine.
In particular, the CLINAM Summit emerged as exquisite forum for translation from bench to bedside, for European and international networking, and for industrial collaboration between companies, with academia, and point-of-contact with customers. The summit is presently the only place to meet the regulatory authorities from all continents to debate the needs of all stakeholders in the field with the legislators.
CLINAM 9/2016continues with its successful tradition to cover the manifold interdisciplinary fields of Clinical and Targeted Nanomedicine in major and neglected diseases. As special focus area, CLINAM 09/2016 adds translation and enabling technologies, including, for example, cutting-edge molecular profiling, nano-scale analytics, single cell analysis, stem cell technologies, tissue engineering, in and ex vivo systems as well as in vitro substitute systems for efficacy and toxicity testing.
CLINAM 09/2016covers the entire interdisciplinary spectrum of Nanomedicine and Targeted Medicine from new materials with potential medical applications and enabling technologies over diagnostic and therapeutic translation to clinical applications in infectious, inflammatory and neurodegenerative diseases, as well as diabetes, cancer and regenerative medicine to societal implications, strategical issues, and regulatory affairs. The conference is sub-divided into four different tracks running in parallel and provides ample possibilities for exhibitors as indicated by steadily increasing requests:
The Tracks and Topics of the Conference
Track 1: Clinical and Targeted Nanomedicine – Basic Research • Disease Mechanisms and Personalized Medicine • Regenerative Medicine • Novel Therapeutic and Diagnostic Approaches • Active and Passive Targeting • Targeted Delivery (antibodies, affibodies, aptamers, nano drug delivery devices) • Accurin Technology •Nano-Toxicology Track 2: Clinical and Targeted Nanomedicine: Translation • Unsolved Medical Problems• Personalized Medicine and Theranostic Approaches • Regenerative Medicine • Advanced Breaking and Ongoing Clinical Trials • Applied Nanomedical Diagnostics and Therapeutics Track 3: Enabling Technologies• Nanomaterial Analytics and Testing • Molecular Profiling for Research and Efficacy/Toxicology Testing (Genomics, Proteomics, Glycomics, Lipidomics, Metabolomics) • Functional Testing Assays and Platforms• Single Cell Analyses • Cell Tracking • Stem Cell Biology and Engineering Technologies • Microfluidics • Tissue Engineering – Tissues-on-a-Chip – Bioprinting •In vivo Testing •Novel Imaging Approaches • Medical Devices Track 4: Regulatory, Societal Affairs and Networking • Regulatory Issues in Nanomedicine • Strategy and Policy • The Patients` Perspective • Ethical Issues in Nanomedicine • University Village • Cutting-Edge EU-Project Presentations • Networking for International Consortium Formation
The Exhibition as mirror of the Conference
For CLINAM 9 / 16 Last Summit the number of exhibitors increased without investment of acquisition.As from the 9th Summit the CLINAM-Foundation has stepped in to a Partnership with The Congress Center Basel which will invest in a proactive acquisition and management for large foyer exhibition. Based on last year’s exhibition it is expected to have about 50 Exhibitors at thenext Summit. Exhibitors can profit of the possibility to meet their target visitors on one single spot in Basel at CLINAM 9 / 2016. With this new concept for the exhibition, the international CLINAM-summit becomes also the place for the pulse of the market and early sales in the field of cutting-edge medicine.
The exhibitors are invited to participate in the below in the nomenclature described fields. The list is topic to extensions so that by proposals from exhibitors it will constantly be updated. Strong focus of the exhibition relates to the topics of the conference in which Nanomedicine and Targeted Medicine - presently the most important building blocks in novel Medicine - are debated. The organizers look forward to the interest of the exhibitors to at a moderate investment take the opportunity to meet the community of Nanomedicine, Targeted Medicine and those investing into cutting edge Medicine tools and applications.
Call for Papers
The CLINAM- Summit has every year 150 presentations. Many young mist skilled young researchers, young starting entrepreneurs, Engineers and scientists apply for posters and oral presentations.
CLINAM offers a first Deadline for those, submitting their work before February 15, 2016 a discount of 20% on the registration fees for Submitters (610.00 €; for students 430.00 €) . The second Deadline after that is April 25, 2016
Collaborating Parties in 2015
The Exhibitors at CLINAM 8/2015
The European Foundation for Clinical Nanomedicine is a non-profit institution aiming at advancing medicine to the benefit of individuals and society through the application of nanoscience. Aiming at prevention, diagnosis, and therapy through nanomedicine as well as at exploration of its implications, the Foundation reaches its goals through support of clinically focussed research and of interaction and information flow between clinicians, researchers, the public, and other stakeholders. The recognition of the large future impact of nanoscience on medicine and the observed rapid advance of medical applications of nanoscience have been the main reasons for the creation of the Foundation.
Nanotechnology for Medicine
Nanotechnology is generally considered as the key technology of the 21st century. It is an interdisciplinary scientific field focusing on methods, materials, and tools on the nanometer scale, i.e. one millionth of a millimeter. The application of this science to medicine seeks to benefit patients by providing prevention, early diagnosis, and effective treatment for prevalent, for disabling, and for currently incurable medical conditions.